BioSpace News Archive

Edesa Biotech, Inc. today reported that the company and the U.S. Food and Drug Administration (FDA) have agreed on the primary endpoint and population for a pivotal Phase 3 study evaluating Edesa’s monoclonal antibody candidate, EB05, as a therapy for hospitalized patients with a severe form of respiratory failure.

Dyadic International, Inc. today announced that it will report its financial results for the year ended 2022 and host a corporate update conference call on Wednesday, March 29, 2023.

Acer Therapeutics Inc. (Nasdaq: ACER) today announced data will be presented from a survey designed to quantify preferences of healthcare providers for Urea Cycle Disorders (UCDs) at the upcoming 44th Annual Meeting of the Society for Inherited Metabolic Disorders (SIMD), March 18th-21st in Salt Lake City, Utah.

Inhibikase Therapeutics, Inc. provided an interim update from the dose escalation portion of its ‘501' bioequivalence study of IkT-001Pro, the Company’s prodrug formulation of imatinib mesylate designed to enhance the safety and efficacy of imatinib in patients with Chronic Myelogenous Leukemia.

MiNK Therapeutics, Inc. (NASDAQ: INKT), today announced plans to present updated clinical data and development plans in solid tumors at the American Association for Cancer Research (AACR) Annual Meeting, April 14-19th, 2023.

Today, Kurve Therapeutics (Kurve Tx) announced it has filed for new intellectual property on its nose-to-brain technology platform.

Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced that its Investigational New Drug (IND) application for the investigation of CT1812 for geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD) has been cleared by the U.S. Food and Drug Administration (FDA).

Vivace Therapeutics, Inc. today announced that the first clinical data for a cancer treatment targeting the Hippo pathway will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2022.

LGM Pharma today reported strong growth in 2022 in both its long-established Active Pharmaceutical Ingredient (API) division and its new contract development and manufacturing (CDMO) division.

Protagonist Therapeutics, Inc. today announced positive topline results from the blinded, placebo-controlled, randomized withdrawal portion of REVIVE achieved highly statistically significant improvements versus placebo in the primary endpoint.